New Company Twelve Bio Aims To Improve On CRISPR Gene-Editing Tech
Cas12a Offers Advantages
Venture capital firm Arix is financing the Copenhangen, Denmark-based biotech, which is looking to play its part in the fast-maturing gene-editing field.
You may also be interested in...
With more data reported at ASH, Vertex and CRISPR Therapeutics added heft to the notion that functional cures are on the horizon for the inherited blood disorders sickle cell disease and beta-thalassemia. Attention is now turning to Bluebird’s marketing strategy after a filing delay.
The UK biotech aims to raise $100m, but will need to tackle safety concerns to secure a long-term future.
Sanofi has paid out $160m to add to its in-house expertise in mRNA and novel cell therapy technologies.